Drug intelligence / Profile preview

inactivated SARS-CoV-2 vaccine + quadrivalent influenza vaccine

Development stage
Unknown
Lead developer
Sinovac Biotech
Modality
Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

A combination vaccine composed of an inactivated SARS-CoV-2 (COVID-19) vaccine and a quadrivalent influenza vaccine. The inactivated SARS-CoV-2 component is designed to induce immunity against the coronavirus responsible for COVID-19, while the quadrivalent influenza component targets two strains of influenza A and two strains of influenza B viruses. The mechanism of action involves stimulating the immune system to produce antibodies against both SARS-CoV-2 and seasonal flu viruses, thereby providing protection against both diseases. This type of combination aims to simplify immunization schedules, improve compliance, and broaden protection during respiratory virus seasons. Several companies are developing such combination vaccines using different platforms (e.g., mRNA-based or protein-based), but "inactivated" refers specifically to vaccines where viral particles have been killed so they cannot cause disease but still elicit an immune response.

02

Targets

HA (Hemagglutinin)SARS-CoV-2 spike

Beyond the preview

Go deeper on inactivated SARS-CoV-2 vaccine + quadrivalent influenza vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on inactivated SARS-CoV-2 vaccine + quadrivalent influenza vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call